June 2006

Topical Photodynamic Therapy With Methyl Aminolevulinate to Treat Sebaceous Hyperplasia in an Organ Transplant Recipient

Author Affiliations

Copyright 2006 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2006

Arch Dermatol. 2006;142(6):781-798. doi:10.1001/archderm.142.6.781

Sebaceous hyperplasia (SH), a benign proliferation of the sebaceous glands, develops as a consequence of aging, exposure to UV radiation, and immunosuppression. Organ transplant recipients are susceptible to SH,1 particularly on the face, where multiple large lesions may cause cosmetic concern.

A 43-year-old male renal transplant recipient receiving long-term immunosuppressive therapy developed more than 100 SH lesions on his face within 3 years of transplantation. He found these lesions particularly unsightly (Figure 1). Cryotherapy and carbon dioxide laser treatment provided some improvement, but the hypopigmentation that developed posttreatment was unsightly. Further treatment with these methods was not attempted.

First Page Preview View Large
First page PDF preview
First page PDF preview